Zymeworks(Zymeworks)胜过收入估算,损失比预期要少,收入飞涨,同时推进癌症药物试验。 Zymeworks beat earnings estimates with a smaller-than-expected loss and soaring revenue, while advancing cancer drug trials.

Zymeworks报告,每季度每股损失0.26美元,预期损失0.30美元,收入比上一年增加72.6%。 Zymeworks reported a quarterly loss of $0.26 per share, beating expectations of a $0.30 loss, with revenue up 72.6% year-over-year. 临床阶段生物制药公司在试验中继续推进其癌症治疗zanidatamab和ZW49。 The clinical-stage biopharma company continues advancing its cancer treatments zanidatamab and ZW49 in trials. 尽管股本和净差值出现负回报,但股票关闭17.90美元,交易量增加。 Despite a negative return on equity and net margin, the stock closed at $17.90 with elevated trading volume. 分析师保持“Buy”共识评级,但公司尚未提供2025年指导。 Analysts maintain a "Buy" consensus rating, but the company has not provided 2025 guidance.